30. The method according to claim 29, wherein said alkali metal periodate oxidizes *cis*-glycol groups of the glycan moieties to aldehyde groups.

31. The method according to claim 30, wherein said alkali metal borohydride reduces said aldehydes to alcohols.

32. A modified sulfamidase obtainable by the method according to any one of claims 18-31.

33. The modified sulfamidase or the sulfamidase composition according to any one of claims 1-17 and 32, for use in therapy.

34. The modified sulfamidase or the sulfamidase composition according to claim 33, for use in treatment of a mammal afflicted with a lysosomal storage disease, in particular mucopolysaccharidosis IIIA (MPS IIIA).

35. A method of treating a mammal afflicted with a lysosomal storage disease, such as mucopolysaccharidosis IIIA (MPS IIIA), comprising administering to the mammal a therapeutically effective amount of a modified sulfamidase, said modified sulfamidase being selected from:

a) a modified sulfamidase according to any one of claims 1-14 and 32;
b) a sulfamidase composition according to any one of claims 15-17, and
c) a modified sulfamidase wherein the modification comprises sequential treatment of said modified sulfamidase with an alkali metal periodate and an alkali metal borohydride, whereby the sulfamidase has its glycan moieties chemically modified so as to reduce its activity with respect to glycan recognition receptors while retaining catalytic enzymatic activity.

30. The method according to claim 29, wherein said alkali metal periodate oxidizes *cis*-glycol groups of the glycan moieties to aldehyde groups.

31. The method according to claim 30, wherein said alkali metal borohydride reduces said aldehydes to alcohols.

32. A modified sulfamidase obtainable by the method according to any one of claims 18-31.

33. The modified sulfamidase or the sulfamidase composition according to any one of claims 1-17 and 32, for use in therapy.

34. The modified sulfamidase or the sulfamidase composition according to claim 33, for use in treatment of a mammal afflicted with a lysosomal storage disease, in particular mucopolysaccharidosis IIIA (MPS IIIA).